CXCR3 and ovarian carcinoma: In contrast to prior reports demonstrating induction of CXCR3 chemokines upon immune checkpoint inhibition in preclinical models other than ovarian cancer [9], we did not observe such an increase in the ID8 ovarian cancer model (Fig. 2c and Supplementary Fig. S2A).